Dr Reddy's and Argenta seek treatment for respiratory disease
Dr Reddy's Laboratories of India is to jointly develop a new approach to the treatment of chronic obstructive pulmonary disease (COPD) with Argenta Discovery of Harlow, UK.
Dr Reddy's Laboratories of India is to jointly develop a new approach to the treatment of chronic obstructive pulmonary disease (COPD) with Argenta Discovery of Harlow, UK.
The two companies will collaborate to identify clinical candidates among compounds from the Indian drug company. Both the parties will jointly develop the selected candidates from the pre-clinical stage up to Phase IIa (proof-of-concept). No financial terms were disclosed.
Privately-held Argenta applies integrated medicinal chemistry, biology, ADMET and CADD expertise to advance clients' drug discovery programmes. Its in-house programmes focus on respiratory disease, specifically COPD, severe asthma and cystic fibrosis.
COPD is the fourth leading cause of morbidity in the world and the global COPD and asthma treatment market is currently valued at $12bn is expected to reach $16bn by 2012.